Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an overweight rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Up 1.3 %

Shares of VNDA opened at $5.29 on Thursday. The company has a market capitalization of $308.35 million, a price-to-earnings ratio of -66.13 and a beta of 0.75. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The stock’s 50-day moving average price is $5.60 and its 200-day moving average price is $5.06.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The firm had revenue of $50.47 million for the quarter. As a group, equities analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Raymond James & Associates purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth $42,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at about $87,000. Aristides Capital LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $272,000. GSA Capital Partners LLP raised its position in shares of Vanda Pharmaceuticals by 39.8% during the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 161,737 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 17.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock valued at $1,772,000 after buying an additional 64,670 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.